Telpres of the tab. of 40 mg No. 28

tablets "Telpres" are applied at the following indications:

• hypertensia (treatment of essential hypertensia at adults);
• prevention of cardiovascular diseases at patients with:
  • significant manifestations of an aterotrombotichesky cardiovascular disease (coronary heart disease, stroke or damages of peripheral arteries in the anamnesis);
  • diabetes of the II type with the diagnosed damage of target organs.

Structure

Active ingredient - telmisartan (one tablet supports a telmizartan of 40 mg).

Excipients: sodium hydroxide, povidone, Megluminum, attracts (E 421), krospovidon, magnesium stearate.

Contraindication

• hypersensitivity to active ingredients or any excipient of drug;
• obstructive diseases of bile ducts;
• heavy abnormal liver functions;
• simultaneous use of a telmizartan and aliskiren to patients with diabetes or renal failures (SKF <60 ml/minute / 1.73 m ² );
• pregnancy or pregnancy planning;
• feeding period breast;
• children's age (up to 18 years).

Route of administration

Telpres is accepted 1 time a day orally with enough liquid irrespective of meal.

Telpres should be stored in tight blister packing as tablets are very hygroscopic. To take out tablets from the blister just before use.

Treatment of essential hypertensia

Usual effective dose makes 40 mg a day. To some patients the daily dose of 20 mg can be sufficient. In case desirable arterial blood pressure is not reached, the dose of a telmizartan can be raised to 80 mg of 1 times a day. Alternatively telmizartan it is possible to appoint in a combination with thiazide diuretics, such as hydrochlorothiazide which showed an additional lowering of arterial pressure at use with telmisartany. When the question of increase in a dose is considered, it is necessary to take into account that the maximum antihypertensive effect in general is reached in 4-8 weeks from an initiation of treatment.

Prevention of cardiovascular diseases

Recommended dose makes 80 mg of 1 times a day. The efficiency of a telmizartan in doses less than 80 mg at prevention of cardiovascular diseases is unknown.

treatment telmisartany for the purpose of prevention of cardiovascular diseases, it is recommended to carry out monitoring of arterial blood pressure and in case of need to adjust a dose of the medicaments reducing arterial blood pressure.

Feature of use

Drivers

At antihypertensive therapy, including telmisartany, at control of motor transport or other mechanisms it is necessary to consider possibility of dizziness or a hypersomnia.

Information on overdose telmisartany is limited to

.

Symptoms

Most significant manifestations of overdose of a telmizartan were arterial hypotension and tachycardia; also there were bradycardia cases, dizziness, increase in creatinine in blood serum and an acute renal failure.

Treatment

Telmizartan does not leave from an organism by a hemodialysis. In case of overdose for the patient it is necessary to establish careful observation and to appoint symptomatic and maintenance therapy. The choice of treatment depends on time which passed after introduction, and from weight of symptoms. It is necessary to consider such measures as stimulation of vomiting and/or gastric lavage. Activated carbon can be useful in overdose treatment. It is necessary to control often the level of electrolytes and creatinine in serum. At appearance of arterial hypotension of the patient it is necessary to put in a prone position and to quickly enter substitutes of salt and to restore liquid volume.

Serious side reactions including anaphylactic reactions and a Quincke's disease are possible

in rare instances (from ≥ 1/10,000 to <1/1000) and also the acute renal failure was observed.

Storage conditions

to Store

in original packing at a temperature not above 25 °C, out of children's reach.

Expiration date - 3 years.